229 related articles for article (PubMed ID: 19755995)
1. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.
Stish BJ; Oh S; Chen H; Dudek AZ; Kratzke RA; Vallera DA
Br J Cancer; 2009 Oct; 101(7):1114-23. PubMed ID: 19755995
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
3. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
Oh S; Stish BJ; Sachdev D; Chen H; Dudek AZ; Vallera DA
Clin Cancer Res; 2009 Oct; 15(19):6137-47. PubMed ID: 19789305
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
[TBL] [Abstract][Full Text] [Related]
6. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
8. A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.
Oh S; Todhunter DA; Panoskaltsis-Mortari A; Buchsbaum DJ; Toma S; Vallera DA
Pancreas; 2012 Jul; 41(5):789-96. PubMed ID: 22258068
[TBL] [Abstract][Full Text] [Related]
9. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
11. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Du X; Ho M; Pastan I
J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
[TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
15. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
[TBL] [Abstract][Full Text] [Related]
16. Targeted toxins in brain tumor therapy.
Li YM; Hall WA
Toxins (Basel); 2010 Nov; 2(11):2645-62. PubMed ID: 22069569
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.
Flatmark K; Guldvik IJ; Svensson H; Fleten KG; Flørenes VA; Reed W; Giercksky KE; Fodstad Ø; Andersson Y
Int J Cancer; 2013 Sep; 133(6):1497-506. PubMed ID: 23494569
[TBL] [Abstract][Full Text] [Related]
18. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
Theuer CP; Pastan I
Am J Surg; 1993 Sep; 166(3):284-8. PubMed ID: 8368439
[TBL] [Abstract][Full Text] [Related]
20. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model.
Hu CC; Ji HM; Chen SL; Zhang HW; Wang BQ; Zhou LY; Zhang ZP; Sun XL; Chen ZZ; Cai YQ; Qin LS; Lu L; Jiang XD; Xu RX; Ke YQ
Int J Cancer; 2010 Nov; 127(9):2222-9. PubMed ID: 20127864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
